Speaker
David Ricks
Appearances over time
1 episodes
Episodes
1
Podcasts
Quotes & moments
Obesity is described as a 'nodal health condition' connected to more than 200 chronic diseases, making GLP-1 treatment uniquely high-leverage.
About a third of all US healthcare spending — roughly $1.4 trillion per year — is obesity-related, comparable in scale to the entire Defense Department budget.
The direct-purchase price for Zepbound has dropped 60% since launch to $399/month through LillyDirect, with the oral Foundeo starting at $159.
Lilly's triple-acting retatrutide demonstrated the most powerful pain-reduction ever recorded pharmacologically for knee arthritis in clinical studies.
Starting July 1, every Medicare senior in America can access Lilly's obesity medication for just $50 out-of-pocket per month, potentially impacting 70 million people.
Eli Lilly reduced its drug development cycle from 11 years to around 6, giving it a substantial competitive advantage in patent-protected market time.
David Ricks estimates that humans have discovered only 10–20% of all knowledge about the human body system, making AI-driven drug discovery extremely difficult today.
Tirzepatide, the active ingredient in Mounjaro and Zepbound, was physically the 700th version of a GLP-1 inhibitor Lilly formulated and tested.
Mississippi has one of the highest adult obesity rates in the US at 78–79%, the highest Medicaid enrollment, and is one of the poorest states — but Lilly just struck a deal to supply its drugs through their Medicaid program.
Eli Lilly has invested approximately $50 billion in new manufacturing facilities in the United States to address drug supply shortages.
Lilly is pursuing brenepatide in Phase 3 trials specifically for alcohol use disorder, after observational data showed GLP-1 users spontaneously drink less.
David Ricks estimates meaningful AI-driven acceleration of drug discovery is roughly a decade away, not the 2–3 years many tech boosters claim.
Patients in GLP-1 trials spontaneously reduced alcohol intake, gambling, and even online shopping without being prompted. Lilly is now pursuing a Phase 3 drug — brenepatide — specifically for alcohol use disorder, as the mechanism appears to quiet hedonic urges broadly.
About a third of all US healthcare spending is obesity-related — roughly $1.4 trillion annually. That's comparable to the entire US Defense Department budget, and it's almost entirely driven by downstream chronic diseases like diabetes, cardiovascular disease, and joint failure.
The booming online peptide market is selling substances without clinical trials, safety data, or FDA approval. Lilly's CEO calls them 'unstudied medicines' — and connects the craze to justified rage at a broken healthcare system that leaves patients feeling financially and informationally powerless.
AI excels at synthesizing existing knowledge, but drug discovery requires creating new knowledge. Humans have mapped only 10–20% of human biology, so AI models trained on that incomplete dataset produce poor predictions. Meaningful AI acceleration in pharma R&D is a 10-year arc, not a 2-year one.
US drug pricing is systemically regressive: the largest institutional buyers get the lowest prices, while uninsured or underinsured individuals pay the most. Lilly created LillyDirect to let consumers buy directly at institutional prices, cutting Zepbound's cost by 60% to $399/month.
Lilly's triple-acting GLP-1 drug retatrutide, expected for launch next year, produced the most powerful pharmacological pain reduction ever recorded for knee arthritis. The finding was unexpected and points to GLP-1s as potential game-changers for America's massive chronic pain burden.
Scott Galloway argues GLP-1s will prove more transformative than AI — which he calls the most overhyped technology — because they address the root cause of America's chronic disease epidemic. He has named GLP-1s his 'technology of the year' for two consecutive years in his annual predictions deck.
GLP-1 drugs don't just help people lose weight — they reduce inflammation, cardiovascular disease risk, and are linked to lower cancer rates. Obesity is a nodal condition upstream of over 200 chronic diseases, making these drugs uniquely high-leverage for public health.
David Ricks stumbled into the pharmaceutical industry because his future wife was in med school in Indianapolis — so he needed a local job. He later moved his family to China to run Lilly China. His advice: stop overprogramming your career path and say yes to opportunities that scare you a little.
Eli Lilly was founded by a Civil War colonel who witnessed battlefield deaths from poor medical care and infections. His revolutionary idea: list every ingredient on the bottle and sign it himself — a commitment to quality and transparency that became the company's founding DNA 150 years before the FDA existed.
Lilly bet on GLP-1s in 2018 when nobody else was — obesity was considered a non-market. Combined with a 5-year cut in R&D cycle time and a singular Midwestern execution culture, those three factors compounded into a trillion-dollar market cap and fivefold stock return.
Starting July 1, every Medicare senior in America can buy Lilly's obesity medication for $50 out-of-pocket per month. This single policy shift could extend GLP-1 access to 70 million people, and represents a meaningful inflection point for both public health and Lilly's volume strategy.
Analysis
What they talk about
- Health & Fitness 37%
- Business 27%
- Society & Culture 18%
- Science 9%
- Technology 9%
Connections
Shows they appear on and people they share episodes with. Drag to explore.
